Key result
Current evidence supports a monotherapy paradigm prioritizing oral anticoagulants or single antiplatelet therapy after transcatheter aortic valve implantation.
Why the study?
TAVI carries a risk of thrombotic complications requiring prevention, but bleeding is a major drawback, necessitating antithrombotic therapy tailored to individual risk.
What is the optimal antithrombotic therapy strategy after transcatheter aortic valve implantation to minimize thrombotic and bleeding complications?
What is the optimal antithrombotic therapy strategy after transcatheter aortic valve implantation to minimize thrombotic and bleeding complications?
The review highlights that current guidelines favor a monotherapy approach (OAC or SAPT) after TAVI to optimize the balance between bleeding and thrombotic risks.
Answers are grounded in this paper and cite their sources.
Supports monotherapy after TAVI to reduce bleeding; reinforces Level 1 evidence for de-escalation.
INTRODUCTION: Transcatheter aortic valve implantation (TAVI) is a treatment option for patients with symptomatic severe aortic stenosis across the entire spectrum of surgical risk. TAVI conveys some risk for thrombotic complications, requiring antithrombotic drugs for their prevention. Bleeding events represent the major drawback of antithrombotic therapy, which should be carefully tailored over the individual patient's risk profile. AREAS COVERED: This review aimed at exploring the rationale for the adoption of a tailored antithrombotic therapy after successful TAVI, with a description and analysis of common complications and their impact on therapy selection. In addition, we aimed at reviewing and discussing current knowledge in this area, with a main focus on the high-quality evidence supporting latest guideline recommendations. Finally, ongoing studies and future directions on antithrombotic therapy after TAVI were outlined. EXPERT OPINION: Initial experience with antithrombotic therapy after TAVI was derived from percutaneous coronary intervention practice. Accruing evidence in the field led to the current monotherapy paradigm, which prioritizes oral anticoagulant and single antiplatelet therapy in patients with or without an established indication for long-term anticoagulation, respectively. Future studies will investigate the role of alternative antithrombotic strategies to improve clinical outcomes of TAVI patients by minimizing both thrombotic and bleeding complications.
No takes yet. Share an insight, caveat, or question.
Greco et al. (2022) conducted a review in Symptomatic severe aortic stenosis undergoing TAVI. Antithrombotic therapy was evaluated. Current evidence supports a monotherapy paradigm prioritizing oral anticoagulants or single antiplatelet therapy after transcatheter aortic valve implantation.
Synapse has enriched 10 related papers. Consider them for comparative context: